Navigation Links
A new model for studying Parkinson's
Date:2/1/2011

Evidence is steadily mounting that genetic factors play an important role in many cases of Parkinson's disease (PD). In a study published February 2, 2011, online in the Journal of Neuroscience, researchers from the Ecole Polytechnique Fdrale de Lausanne (EPFL) in Switzerland report a new mammalian model for studying a specific gene mutation commonly found in PD sufferers, opening the door to new drugs to fight the malady.

"This is a great step forward toward a more comprehensive understanding of how the disease works, and how it can be diagnosed and treated," explains neuroscientist and EPFL President Patrick Aebischer, lead author of the study.

PD is a common neurodegenerative disease that greatly reduces quality of life and costs the United States around 23 billion dollars a year. Until now, researchers have encountered difficulty in reproducing PD pathology in animals because of an incomplete understanding of the disease.

Recently, a mutation of the gene coding for LRRK2, a large enzyme in the brain, has emerged as the most prevalent genetic cause of PD (genetics are implicated in about 10 percent of all PD cases). When the enzyme is mutated, it becomes hyperactive, causing the death of vulnerable neurons and leading to a reduction in levels of the brain neurotransmistter dopamine. This decrease in dopamine eventually triggers the symptoms characteristic of Parkinson's, such as tremors, instability, impaired movement, and later stage dementia.

Now, with funding from the Michael J. Fox Foundation for Parkinson's Research, Aebischer and his team in the Neurodegenerative Studies Laboratory at EPFL, have successfully introduced mutant LRRK2 enzyme into one hemisphere of a rat brain, resulting in the same PD manifestations that occur in humans in one side of the rodent's body. To do this, the researchers spent two years producing and optimizing a viral vector to deliver mutated, LRRK2 coding DNA into the rat brain. LRRK2 i
'/>"/>

Contact: Michael Mitchell
michael.mitchell@epfl.ch
41-798-103-107
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. Model Predicts a Drugs Likelihood of Causing Birth Defects
2. INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model
3. Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinsons Disease
4. New hydrolysis model promising tool in cellulosic biofuel studies
5. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
6. Jeffrey Mogil to Speak on Animal Models of Pain at Arrowhead's 4th Annual Pain Therapeutics Summit
7. Zymes’ Water Soluble CoQ10 Decreases Symptoms in Animal Models of Parkinson’s Disease
8. Zenith Biotech Introducing Novel StemQ(R) Hepatic and Neural Models for Use in Drug Discovery, Metabolism and Toxicology Studies, at The 49th Annual Meeting and ToxExpo In Salt Lake City, Utah, March 7-11, 2010, Booth #136
9. Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities
10. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
11. Biomodels Scientists Report Development of a Novel Model for Cancer Treatment-Related Fatigue
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A new model for studying Parkinson's
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... poster presentation at the International Society for Cellular ... chronic Achilles tendinosis currently in a Phase 1/2 ... 29 th from 5:30 PM to 7:00 ...
(Date:5/20/2015)... SOUTH SAN FRANCISCO, Calif. , May 20, ... VCYT ) today presented preliminary data demonstrating ... help distinguish idiopathic pulmonary fibrosis (IPF) from other ... bronchoscopy. The findings suggest the classifier,s potential to ... expensive surgery to resolve ambiguity in IPF diagnosis ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... of the "Global Cell Therapy Market Outlook 2020 ... of cell therapy in tissue and regenerative medicine is ... no other options which could help in the growth ... this segment but they are unable to form new ...
(Date:5/20/2015)... 2015  Health eCareers, the healthcare industry,s online ... job seekers looking for the flexibility of short-term ... and online tool dedicated exclusively to temporary and ... SHIFT enables employers to quickly find and hire ... diem and other temporary positions, eliminating the time ...
Breaking Biology Technology:RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... 27 Following the successful acquisition of,Drug Development ... organization, announced today that it has fully,integrated its ... branded as,Chiltern Early Phase., Chiltern Early Phase ... pharmaceutical industry via its two well established units ...
... 26 Based on its recent analysis,of the ... presents Kionix, Inc. with the 2008 Global Frost ... a leadership position,in analog output accelerometer products, and ... KXSC7 accelerometer release, a natural extension of,its product ...
... Industries is,pleased to announce the addition of long ... newest member on their Board of Directors., ... Mr.,Skiven oversaw during his 15 years as Executive ... logical that he would join the board of ...
Cached Biology Technology:Chiltern Early Phase: Fully Integrated and Business Ready 2Frost & Sullivan Recognizes Kionix's Dominance in the MEMS Accelerometers Market Through Product Line Strategy 2Frost & Sullivan Recognizes Kionix's Dominance in the MEMS Accelerometers Market Through Product Line Strategy 3Frost & Sullivan Recognizes Kionix's Dominance in the MEMS Accelerometers Market Through Product Line Strategy 4GM Exec Joins Bio-Reaction Industries' Board of Directors 2
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... A 23andMe study of consumers, reactions to genetic testing ... in individuals, those individuals had few negative reactions to ... results prompted people to take positive steps, including follow-up ... who could also be at risk. The study, ...
... researchers "cured" a strain of bacteria of its ability ... implications for a long-standing public health crisis. ... to remove the ability of the Pseudomonas aeruginosa microorganism ... access to food and oxygen. Over 120 ...
... researcher has identified characteristics in benign breast disease ... Michele Cote, Ph.D., associate professor of oncology ... Ann Karmanos Cancer Institute, recently reviewed data from ... underwent breast biopsies between 1997 and 2000. Researchers ...
Cached Biology News:Consumers have few negative reactions to the results of genetic testing for cancer mutations 2Lack of energy an enemy to antibiotic-resistant microbes 2Lack of energy an enemy to antibiotic-resistant microbes 3Cancer risk for African-American women with benign breast disease factors Wayne State finds 2
...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
...
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Biology Products: